cp wire

CP Wire Articles

Intercept Presents Data form Ph III Substudy That Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver... read more

Fri, 04/13/18 - 12:52 pm
MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today presented the positive... read more

Fri, 04/13/18 - 12:42 pm
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Gilead Sciences, Inc. (Nasdaq: GILD) today presented data from a proof-of-concept study of investigational combination therapies for patients with advanced fibrosis due to nonalcoholic... read more

Fri, 04/13/18 - 12:10 pm
Allergan Announces Launch of the TrueTear Intranasal Neurostimulation Device


Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced the official launch of TrueTear, the first and only FDA-cleared device developed to temporarily increase... read more

Fri, 04/13/18 - 09:47 am
Galapagos Announces ISABELA Ph III Study in Idiopathic Pulmonary Fibrosis



  • GLPG1690 has orphan drug status in US and Europe
  • Ph II results showed disease stabilization over 12 week period
  • ISABELA intended to support NDA and MAA in... read more
Thu, 04/12/18 - 08:26 pm

Pages